Traded Nov 13 – Nov 17, 2026 · largest single transaction ~$411K
Insider buying
Their first buy on recordTraded Jun 17 · filed 5 days later
Since the trade −13.5% · S&P 500 −1.1% · to Nov 17
A major shareholder of Pasithea Therapeutics paid $53K out of pocket for Pasithea Therapeutics shares.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded May 1 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
3 insiders in a week, a first since 2022Traded Nov 28, 2025 · filed 3 days later
Since the trade −70.5% · S&P 500 +7.2% · to Nov 17
A Pasithea Therapeutics director paid $100K out of pocket for Pasithea Therapeutics shares. 2 other people at Pasithea Therapeutics bought some too, in the same month. Shares held went up 201% with this purchase.
Insider buying
3 insiders in a week, a first since 2022Traded Nov 28, 2025 · filed 3 days later
Since the trade −70.5% · S&P 500 +7.2% · to Nov 17
The CEO of Pasithea Therapeutics paid $25K out of pocket for Pasithea Therapeutics shares. 2 other people at Pasithea Therapeutics bought some too, in the same month. Shares held went up 83% with this purchase.
Insider buying
3 insiders in a week, a first since 2022Traded Nov 28, 2025 · filed 3 days later
Since the trade −70.5% · S&P 500 +7.2% · to Nov 17
A Pasithea Therapeutics director paid $25K out of pocket for Pasithea Therapeutics shares. 2 other people at Pasithea Therapeutics bought some too, in the same month. Shares held went up 1333% with this purchase.
Insider filing
Traded Nov 28, 2025 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 28, 2025 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider selling
Traded May 12, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −50.1% · S&P 500 +25.6% · to Nov 17
The CEO of Pasithea Therapeutics sold $792 of Pasithea Therapeutics shares. The filing does not indicate a pre-arranged trading plan.